The genetic test can be performed at home with a gentle cheek swab and allows parents to gain early insight into their baby's health, the company said.
For all conditions covered by the test - including atypical epilepsy, spinal muscular atrophy, and childhood cancers - there are validated medical interventions that may positively influence a baby's future wellbeing when introduced early enough.
"Until now, families have been likely to be caught off-guard by these early-onset diseases, and prognosis is often poor by the time symptoms have manifested," said Eric Schadt, Founder and Chief Executive Officer of Sema4.
"Thanks to breakthroughs in science and medicine, we can now identify babies at risk for these broader set of diseases and deliver interventions - sometimes as simple as vitamin supplements - in time to make a real difference," said Schadt.
Sema4 Natalis uses advanced DNA sequencing to analyse a baby's genes with the accuracy of next generation technology, the company said.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)